Author(s):
Yogita R. Bagul, Vandana S. Nade, Laxman A. Kawale
Email(s):
ahirey638@gmail.com , kawalevl@rediffmail.com , kawalela@rediffmail.com
DOI:
10.52711/0974-360X.2026.00684 
Address:
Yogita R. Bagul1*, Vandana S. Nade1, Laxman A. Kawale2
1Dept. of Pharmacology, M.V.P.S College of Pharmacy, Nashik, Maharashtra-422002 Affiliated to Savitribai Phule Pune University, Pune.
2Dept. of Pharmaceutical Chemistry, M.V.P.S College of Pharmacy, Nashik, Maharashtra-422002 Affiliated to Savitribai Phule Pune University, Pune.
*Corresponding Author
Published In:
Volume - 19,
Issue - 10,
Year - 2026
ABSTRACT:
Objective: To evaluate the neuroprotective effects of coumaric acid and imeglimin, administered alone and in combination, against rotenone-induced Parkinsonism in rats, with emphasis on behavioral, biochemical, and histopathological outcomes. Methods: Experimental Parkinsonism was induced in wistar rats using rotenone (3 mg/kg. s.c) for 21 days. Pretreatment with coumaric acid (80 and 100 mg/kg, p.o.), imeglimin (100 and 200 mg/kg, p.o.), and their combination was administered orally for 21 days. Behavioral assessments were performed using, open field test, locomotor activity, rota rod test and hole-board test. Biochemical estimations of dopamine, brain-derived neurotrophic factor (BDNF), a-synuclein, tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1ß), and antioxidant parameters were determined along with histopathological examination of brain tissue to evaluate neuroprotective effects. Results: Rotenone administration significantly impaired motor coordination, exploratory behavior, and locomotor activity while increasing oxidative stress and neuroinflammatory markers. Dopamine and BDNF levels were markedly reduced, whereas a-synuclein, TNF-a, and IL-1ß levels were significantly elevated in rotenone-treated rats. Treatment with coumaric acid and imeglimin significantly improved behavioral performance and restored antioxidant enzyme levels compared with the rotenone treated group. Both treatments also elevated dopamine and BDNF levels while reducing a-synuclein accumulation and inflammatory cytokines. The combination treatment demonstrated greater neuroprotective effects than individual treatments. Conclusion: Coumaric acid and imeglimin exhibited significant neuroprotective activity against rotenone-induced Parkinsonism through antioxidant, anti-inflammatory, and dopaminergic neurorestorative mechanisms. The findings suggest their potential therapeutic value in the management of Parkinson’s disease.
Cite this article:
Yogita R. Bagul, Vandana S. Nade, Laxman A. Kawale. Neuroprotective Effect of Coumaric acid and Imeglimin against Rotenone-induced Parkinsonism in Rats. Research Journal Pharmacy and Technology. 2026;19(10):4909-8. doi: 10.52711/0974-360X.2026.00684
Cite(Electronic):
Yogita R. Bagul, Vandana S. Nade, Laxman A. Kawale. Neuroprotective Effect of Coumaric acid and Imeglimin against Rotenone-induced Parkinsonism in Rats. Research Journal Pharmacy and Technology. 2026;19(10):4909-8. doi: 10.52711/0974-360X.2026.00684 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-10-60
REFERENCES:
1. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology. 2017; 9(7): a028035. https://doi.org/10.1101/cshperspect.a028035.
2. Gitler AD, Dhillon P, Shorter J. Neurodegenerative disease: Models, mechanisms, and a new hope. Disease Models and Mechanisms. 2017; 10(5): 499-504. https://doi.org/10.1242/dmm.030205.
3. Hussain R, Zubair H, Pursell S, Shahab M. Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches. Brain Sciences. 2018; 8(9): 177. https://doi.org/10.3390/brainsci8090177.
4. Muhammad SN, et al. Protective effect of hirsutidin against rotenone-induced Parkinsonism via inhibition of caspase-3/interleukins-6 and 1β. ACS Omega. 2023; 8: 13016-13025. https://doi.org/10.1021/acsomega.3c00589.
5. Bhardwaj, et al. Parkinson's disease: An insight into mechanisms and model systems. International Journal of Medical Research and Health Sciences. 2018; 7(9): 38-51.
6. Roychowdhury S, et al. Neuroprotective potential of p-coumaric acid in neurodegenerative disorders: A review. Biomedicine and Pharmacotherapy. 2021; 140: 111748. https://doi.org/10.1016/j.biopha.2021.111748.
7. Sinha D. Pharmacological importance of polyphenols: A review. International Research Journal of Pharmacy. 2019; 10(9): 1-11. https://doi.org/10.7897/2230-8407.1009257.
8. Ratheesh G, et al. Role of medicinal plants in neurodegenerative diseases. Biomanufacturing Reviews. 2017;2(2):1-16. https://doi.org/10.1007/s40898-017-0013-y.
9. Mao XY. Drug repurposing in neurological diseases: Opportunities and challenges. In: Drug Repurposing: Hypothesis, Molecular Aspects and Therapeutic Applications. Singapore: Springer; 2020. p.79-87. https://doi.org/10.1007/978-981-15-6426-0_5.
10. Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes, Obesity and Metabolism. 2012; 14(9): 852-858. https://doi.org/10.1111/j.1463-1326.2012.01668.x.
11. Bassani TB, Gradowski RW, Zaminelli T, Barbiero JK, Santiago RM, Boschen SL, et al. Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Research. 2014;1593:95-105. https://doi.org/10.1016/j.brainres.2014.09.068.
12. Sharma N, Bafna P. Effect of Cynodon dactylon on rotenone-induced Parkinson's disease. Oriental Pharmacy and Experimental Medicine. 2012; 12(3): 167-175. https://doi.org/10.1007/s13596-012-0075-1.
13. Mohammad HMF, El-Baz AA, Mahmoud OM, Khalil S, Atta R, Imbaby S. Protective effects of evening primrose oil on behavioral activities, nigral microglia and histopathological changes in a rat model of rotenone-induced Parkinsonism. Journal of Chemical Neuroanatomy. 2023; 127: 102206. https://doi.org/10.1016/j.jchemneu.2022.102206.
14. Sharma N, Jamwal S, Kumar P. Beneficial effect of antidepressants against rotenone-induced Parkinsonism-like symptoms in rats. Pathophysiology. 2016;23(2):123-134. https://doi.org/10.1016/j.pathophys.2016.03.002.
15. Sakamula R, Thong-asa W. Neuroprotective effect of p-coumaric acid in mice with cerebral ischemia-reperfusion injuries. Metabolic Brain Disease. 2018; 33(3): 765-773. https://doi.org/10.1007/s11011-018-0185-7.
16. Singh R, Zahra W, Singh SS, Birla H, Rathore AS, Keshri PK, et al. Oleuropein confers neuroprotection against rotenone-induced model of Parkinson's disease via the BDNF/CREB/Akt pathway. Scientific Reports. 2023; 13(1): 2452. https://doi.org/10.1038/s41598-023-29287-4.
17. Dhanasekaran M, Tharakan B, Manyam BV. Antiparkinsonian drug Mucuna pruriens shows antioxidant and metal-chelating activity. Phytotherapy Research. 2008; 22(1): 6-11. https://doi.org/10.1002/ptr.2273.
18. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Movement Disorders. 1994; 9(1): 92-97. https://doi.org/10.1002/mds.870090115.
19. Sharma S, Kumar P, Deshmukh R. Neuroprotective potential of spermidine against rotenone-induced Parkinson's disease in rats. Neurochemistry International. 2018; 116: 104-111. https://doi.org/10.1016/j.neuint.2018.02.010.
20. Wang T, Li C, Han B, Wang Z, Meng X, Zhang L, et al. Neuroprotective effects of danshensu on rotenone-induced Parkinson's disease models in vitro and in vivo. BMC Complementary Medicine and Therapies. 2020; 20: 320. https://doi.org/10.1186/s12906-019-2738-7.
21. Ahmed S, El-Sayed MM, Kandeil MA, Khalaf MM. Empagliflozin attenuates neurodegeneration through antioxidant, anti-inflammatory, and modulation of α-synuclein and Parkin levels in rotenone-induced Parkinson's disease in rats. Saudi Pharmaceutical Journal. 2022; 30(6): 863-873. https://doi.org/10.1016/j.jsps.2022.03.005.
22. Wang MS, Boddapati S, Emadi S, Sierks MR. Curcumin reduces α-synuclein-induced cytotoxicity in a Parkinson's disease cell model. BMC Neuroscience. 2010; 11: 57. https://doi.org/10.1186/1471-2202-11-57.
23. Tapias V, Cannon JR, Greenamyre JT. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. Journal of Neuroscience Research. 2010; 88(2): 420-427. https://doi.org/10.1002/jnr.22168.
24. Kuang L, Cao X, Lu Z. Baicalein protects against rotenone-induced neurotoxicity through induction of autophagy. Biological and Pharmaceutical Bulletin. 2017; 40(9): 1537-1543. https://doi.org/10.1248/bpb.b17-00392
25. Bekinschtein P, Cammarota M, Medina JH. BDNF and memory processing. Neuropharmacology. 2014; 76: 677-683. https://doi.org/10.1016/j.neuropharm.2013.04.024.
26. Zaitone SA, Abo-Elmatty DM, Elshazly SM. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian Journal of Pharmacology. 2012; 44(6): 774-779. https://doi.org/10.4103/0253-7613.103300.
27. Mbiydzenyuy NE, Ninsiima HI, Valladares MB, et al. Zinc and linoleic acid pretreatment attenuates biochemical and histological changes in the midbrain of rats with rotenone-induced Parkinsonism. BMC Neuroscience. 2018; 19: 29. https://doi.org/10.1186/s12868-018-0429-9.
28. Fikry H, Saleh LA, Abdel Gawad S. Neuroprotective effects of curcumin on the cerebellum in a rotenone-induced Parkinson's disease model. CNS Neuroscience and Therapeutics. 2022; 28(5): 732-748. https://doi.org/10.1111/cns.13805.
29. Ramkumar M, Rajasankar S, Gobi VV, Janakiraman U, Manivasagam T, Thenmozhi AJ, et al. Demethoxycurcumin, a natural derivative of curcumin, abrogates rotenone-induced dopamine depletion and motor deficits by its antioxidative and anti-inflammatory properties in Parkinsonian rats. Pharmacognosy Magazine. 2018; 14(53): 9-16. https://doi.org/10.4103/pm.pm_113_17.
30. Khatri DK, Juvekar AR. Neuroprotective effect of curcumin as evinced by abrogation of rotenone-induced motor deficits, oxidative and mitochondrial dysfunctions in a mouse model of Parkinson's disease. Pharmacology Biochemistry and Behavior. 2016; 150-151: 39-47. https://doi.org/10.1016/j.pbb.2016.09.002.
31. Bashkatova V, Alam M, Vanin A, Schmidt WJ. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Experimental Neurology. 2004; 186(2): 235-241. https://doi.org/10.1016/j.expneurol.2003.12.005.
32. Von Wrangel C, Schwabe K, John N, Krauss JK, Alam M. The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological findings. Behavioural Brain Research. 2015; 279: 52-61. https://doi.org/10.1016/j.bbr.2014.11.002.
33. Ulusoy GK, Celik T, Kayir H, Gürsoy M, Isik AT, Uzbay TI. Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease. Brain Research Bulletin. 2011; 85(6): 380-384. https://doi.org/10.1016/j.brainresbull.2011.05.001.
34. Thakur P, Nehru B. Inhibition of neuroinflammation and mitochondrial dysfunction by carbenoxolone in the rotenone model of Parkinson's disease. Molecular Neurobiology. 2015; 51(1): 209-219. https://doi.org/10.1007/s12035-014-8769-7.
35. Panov A, Dikalov S, Shalbuyeva N, Taylor G, Sherer T, Greenamyre JT. Rotenone model of Parkinson disease: Multiple brain mitochondria dysfunctions after short-term systemic rotenone intoxication. Journal of Biological Chemistry. 2005; 280(51): 42026-42035. https://doi.org/10.1074/jbc.M506108200.
36. Ojha S, Javed H, Azimullah S, Abul Khair SB, Haque ME. Neuroprotective potential of ferulic acid in the rotenone model of Parkinson's disease. Drug Design, Development and Therapy. 2015; 9: 5499-5510. https://doi.org/10.2147/DDDT.S90616.
37. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP. Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in a rotenone model of Parkinson's disease in rats. Neuroscience. 2013; 236: 136-148. https://doi.org/10.1016/j.neuroscience.2013.01.032.
38. Saravanan KS, Sindhu KM, Mohanakumar KP. Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. Journal of Pineal Research. 2007; 42(3): 247-253. https://doi.org/10.1111/j.1600-079X.2006.00412.x.
39. Qin J, Wu M, Yu S, Gao X, Zhang J, Dong X, et al. Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease. Toxicology Letters. 2015; 238(3): 70-82. https://doi.org/10.1016/j.toxlet.2015.08.011.
40. Ojha S, Javed H, Azimullah S, Abul Khair SB, Haque ME. Glycyrrhizic acid attenuates neuroinflammation and oxidative stress in a rotenone model of Parkinson's disease. Neurotoxicity Research. 2016; 29(2): 275-287. https://doi.org/10.1007/s12640-015-9579-z.